GlassScriptPhysician profile
Laurel A Campbell
NPI 1063618932
$6,777.31
in general payments reported to CMS, 2019-2025
40 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $1,144 · 2021: $1,964 · 2022: $1,461 · 2023: $166 · 2024: $324 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $901.42 | 2019-2024 | Vraylar |
| Novo Nordisk INC | $641.28 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $502.68 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $350.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $340.69 | 2019-2022 | |
| Lilly USA, LLC | $337.24 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $333.24 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $313.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.98 | 2019-2022 | |
| Abbott Laboratories | $238.21 | 2021-2022 | |
| Amarin Pharma, INC. | $190.84 | 2019-2021 | |
| Eisai INC. | $188.64 | 2020-2022 | |
| Gilead Sciences, INC. | $181.36 | 2019-2023 | Epclusa |
| Biohaven Pharmaceutical Holding Company LTD. | $174.68 | 2022 | |
| Allergan, INC. | $163.24 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.